New Findings from Eulji University Update Understanding of Vitreous Hemorrhage (Antithrombotic Medication and the Risk of Vitreous Hemorrhage In Atrial Fibrillation: Korean National Health Insurance Service National Cohort)

2019 JUN 06 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Business Daily -- Data detailed on Eye Diseases and Conditions - Vitreous Hemorrhage have been presented. According to news reporting originating in Seoul, South Korea, by NewsRx journalists, research stated, “Antithrombotic therapy could be related with nuisance bleeding. This study investigated whether vitreous hemorrhage (VH) is associated with specific types of antithrombotic medication in patients with atrial fibrillation (AF).”

Financial support for this research came from Korean Healthcare technology R&D project - Ministry of Health Welfare.

The news reporters obtained a quote from the research from Eulji University, “In the Korean National Health Insurance Service National Sample Cohort, we identified 9352 antiplatelet/anticoagulant-treated AF patients. The occurrence of VH was compared between warfarin (n=1493) and a propensity score (PS)-matched antiplatelet group (n=1493) and between warfarin (n=1493) and a PS-matched warfarin+antiplatelet group (n=1493). The outcomes of VH were lower in the warfarin than in the matched antiplatelet (1.45 vs. 3.72 events/1000 patient-years) and matched warfarin+antiplatelet groups (1.45 vs. 6.87 events/1.000 patient-years). Compared with warfarin, the risk of VH increased with antiplatelet [adjusted hazard ratio (aHR) 3.90; 95% confidence interval (CI) 1.22-12.4, p=0.022] and warlarin+antiplatelet agents (aHR 4.39,95% CI 1.74-11.2, p=0.002). Compared with warfarin only, warfarin+antiplatelet agents increased the risk of VH in patients 65 years, regardless of gender and hypertension. The risk of VH was significantly higher with dual antiplatelet therapy (aHR: 5.02,95% CI: 1.56-16.2, p=0.007) or in dual (aHR: 5.02,95% CI: 1.74-14.5, p=0.003) or triple therapy using warfarin and antiplatelet agents than with warfarin monotherapy (aHR: 6.12,95%CI: 1.76-21.3, p=0.004). Dual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy.”

According to the news reporters, the research concluded: “Considering the low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplatelet agents should be avoided to prevent VH in AF patients.”

For more information on this research see: Antithrombotic Medication and the Risk of Vitreous Hemorrhage In Atrial Fibrillation: Korean National Health Insurance Service National Cohort. Yonsei Medical Journal, 2019;60(1):65-72. Yonsei Medical Journal can be contacted at: Yonsei Univ Coll Medicine, 50-1 Yonsei-Ro, Seodaemun-Gu, Seoul 120-752, South Korea.

Our news correspondents report that additional information may be obtained by contacting S. Kim, Eulji University, Nowon Eulji Med Ctr, Dept Ophthalrnol, 68 Hangeulbiseok Ro, Seoul 01830, South Korea. Additional authors for this research include K.E. Kim, P.S. Yang, E. Jang and B. Joung.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.3349/ymj.2019.60.1.65. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)